SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/08/19 InMode Ltd. 424B4 1:4.4M Toppan Vintage/FA |
Document/Exhibit Description Pages Size 1: 424B4 Prospectus HTML 1.45M
tv526693-424b4 - none - 38.638152s |
| | |
Per Ordinary
Share |
| |
Total
|
| ||||||
Price to public
|
| | | $ | 14.00 | | | | | $ | 70,000,000 | | |
Underwriting discounts and commissions(1)
|
| | | $ | 0.98 | | | | | $ | 4,900,000 | | |
Proceeds to us (before expenses)
|
| | | $ | 13.02 | | | | | $ | 65,100,000 | | |
| Barclays | | |
UBS Investment Bank
|
|
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 14 | | | |
| | | | 45 | | | |
| | | | 46 | | | |
| | | | 47 | | | |
| | | | 48 | | | |
| | | | 49 | | | |
| | | | 50 | | | |
| | | | 52 | | | |
| | | | 54 | | | |
| | | | 69 | | | |
| | | | 104 | | | |
| | | | 123 | | | |
| | | | 125 | | | |
| | | | 127 | | | |
| | | | 133 | | | |
| | | | 135 | | | |
| | | | 146 | | | |
| | | | 154 | | | |
| | | | 154 | | | |
| | | | 155 | | | |
| | | | 156 | | | |
| | | | 157 | | | |
| | | | F-1 | | |
| | |
Three months ended March 31,
|
| |
Year ended December 31,
|
| ||||||||||||||||||
| | | | |
2018
|
| |
2018
|
| |
2017
|
| |||||||||||||
| | |
(in thousands, except share and per share data)
|
| |||||||||||||||||||||
Consolidated Statements of Income Data: | | | | | | ||||||||||||||||||||
Revenues
|
| | | $ | 30,552 | | | | | $ | 20,911 | | | | | $ | 100,162 | | | | | $ | 53,456 | | |
Cost of revenues
|
| | | | 4,271 | | | | | | 3,532 | | | | | | 15,057 | | | | | | 9,053 | | |
Gross profit
|
| | | | 26,281 | | | | | | 17,379 | | | | | | 85,105 | | | | | | 44,403 | | |
Operating expenses: | | | | | | ||||||||||||||||||||
Research and development
|
| | | | 1,199 | | | | | | 880 | | | | | | 4,180 | | | | | | 2,575 | | |
Sales and marketing
|
| | | | 14,097 | | | | | | 9,665 | | | | | | 44,622 | | | | | | 28,514 | | |
General and administrative
|
| | | | 1,053 | | | | | | 895 | | | | | | 4,814 | | | | | | 4,364 | | |
Legal settlements and loss contingencies
|
| | | | — | | | | | | — | | | | | | 8,000 | | | | | | — | | |
Total operating expenses
|
| | | | 16,349 | | | | | | 11,440 | | | | | | 61,616 | | | | | | 35,453 | | |
Operating income
|
| | | $ | 9,932 | | | | | $ | 5,939 | | | | | $ | 23,489 | | | | | $ | 8,950 | | |
Financial income, net
|
| | | | 403 | | | | | | 278 | | | | | | 136 | | | | | | 849 | | |
Income before taxes
|
| | | $ | 10,335 | | | | | $ | 6,217 | | | | | $ | 23,625 | | | | | $ | 9,799 | | |
Income tax
|
| | | | 177 | | | | | | (149) | | | | | | 1,260 | | | | | | 980 | | |
Net income
|
| | | $ | 10,158 | | | | | $ | 6,366 | | | | | $ | 22,365 | | | | | $ | 8,819 | | |
Net loss (income) attributable to non-controlling
interests |
| | | | (34) | | | | | | — | | | | | | 6 | | | | | | — | | |
Net income attributable to controlling interest
|
| | | $ | 10,124 | | | | | $ | 6,366 | | | | | $ | 22,371 | | | | | $ | 8,819 | | |
Net income per ordinary share: | | | | | | ||||||||||||||||||||
Basic
|
| | | $ | 0.38 | | | | | $ | 0.22 | | | | | $ | 0.82 | | | | | $ | 0.29 | | |
Diluted
|
| | | $ | 0.28 | | | | | $ | 0.17 | | | | | $ | 0.62 | | | | | $ | 0.26 | | |
Weighted average number of ordinary shares: | | | | | | ||||||||||||||||||||
Basic
|
| | | | 26,818,179 | | | | | | 26,497,050 | | | | | | 26,613,942 | | | | | | 26,283,548 | | |
Diluted
|
| | | | 35,457,601 | | | | | | 34,711,741 | | | | | | 35,006,644 | | | | | | 29,669,922 | | |
| | |
As of March 31, 2019
|
| |||||||||
| | |
Actual
|
| |
Pro Forma(1)
|
| ||||||
| | |
(in thousands)
|
| |||||||||
Consolidated Balance Sheet Data: | | | | ||||||||||
Cash and cash equivalents, short-term bank deposits and marketable securities
|
| | | $ | 64,083 | | | | | $ | 127,458 | | |
Working capital(2)
|
| | | | 58,057 | | | | | | 121,432 | | |
Total assets
|
| | | | 85,067 | | | | | | 148,442 | | |
Total liabilities
|
| | | | 27,491 | | | | | | 27,491 | | |
Redeemable non-controlling interest
|
| | | | 2,252 | | | | | | — | | |
Retained earnings
|
| | | | 43,030 | | | | | | 43,030 | | |
Non-controlling interests
|
| | | | 1,441 | | | | | | 3,693 | | |
Total shareholders’ equity
|
| | | | 55,324 | | | | | | 120,951 | | |
| | |
As of March 31, 2019
|
| |||||||||
| | |
Actual
|
| |
Pro Forma
|
| ||||||
| | |
Unaudited
(dollars in thousands, except share data) |
| |||||||||
Cash and cash equivalents, short-term bank deposits and marketable securities
|
| | | $ | 64,083 | | | | | $ | 127,458 | | |
Shareholders’ equity: | | | | | | | | | | | | | |
Ordinary shares, NIS 0.01 par value: 100,000,000 ordinary shares authorized, 26,946,737 shares issued and outstanding, actual; 100,000,000 ordinary shares authorized, 31,946,737 ordinary shares issued and outstanding, pro forma
|
| | | $ | 75 | | | | | $ | 89 | | |
Additional paid-in capital
|
| | | | 10,675 | | | | | | 74,036 | | |
Accumulated other comprehensive income
|
| | | | 103 | | | | | | 103 | | |
Retained earnings
|
| | | | 43,030 | | | | | | 43,030 | | |
Non-controlling interests
|
| | | | 1,441 | | | | | | 3,693 | | |
Total shareholders’ equity
|
| | | $ | 55,324 | | | | | $ | 120,951 | | |
Total capitalization
|
| | | $ | 55,324 | | | | | $ | 120,951 | | |
|
Initial public offering price per ordinary share
|
| |
|
| | | $ | 14.00 | | | |||
|
Net tangible book value per ordinary share as of March 31, 2019
|
| | | $ | 2.10 | | | | | | | | |
|
Increase in net tangible book value per ordinary share attributable to this offering
|
| | | $ | 1.69 | | | | | | | | |
|
Pro forma net tangible book value per ordinary share after this offering
|
| | | | | | | | | $ | 3.79 | | |
|
Dilution per ordinary share to investors in this offering
|
| | | | | | | | | $ | 10.21 | | |
| | |
Ordinary Shares Purchased
|
| |
Total Consideration
|
| |
Average Price Per
Ordinary Share |
| |||||||||||||||||||||
|
Number
|
| |
Percent
|
| |
Amount(1)
|
| |
Percent
|
| ||||||||||||||||||||
Existing shareholders
|
| | | | 26,946,737 | | | | | | 84.3% | | | | | $ | 4,643 | | | | | | 6.2% | | | | | $ | 0.17 | | |
New investors
|
| | | | 5,000,000 | | | | | | 15.7% | | | | | | 70,000 | | | | | | 93.8% | | | | | $ | 14.00 | | |
Total
|
| | | | 31,946,737 | | | | | | 100.00% | | | | | $ | 74,643 | | | | | | 100.00% | | | | | $ | 2.34 | | |
| | |
Three months ended March 31,
|
| |
Year ended December 31,
|
| ||||||||||||||||||
| | | | |
2018
|
| |
2018
|
| |
2017
|
| |||||||||||||
| | |
(in thousands, except share and per share data)
|
| |||||||||||||||||||||
Consolidated Statements of Income Data:
|
| | | | | | | | | | | | | | | | | | | | | | | | |
Revenues
|
| | | $ | 30,552 | | | | | $ | 20,911 | | | | | $ | 100,162 | | | | | $ | 53,456 | | |
Cost of revenues
|
| | | | 4,271 | | | | | | 3,532 | | | | | | 15,057 | | | | | | 9,053 | | |
Gross profit
|
| | | | 26,281 | | | | | | 17,379 | | | | | | 85,105 | | | | | | 44,403 | | |
Operating expenses: | | | | | | | | | | | | | | | | ||||||||||
Research and development
|
| | | | 1,199 | | | | | | 880 | | | | | | 4,180 | | | | | | 2,575 | | |
Sales and marketing
|
| | | | 14,097 | | | | | | 9,665 | | | | | | 44,622 | | | | | | 28,514 | | |
General and administrative
|
| | | | 1,053 | | | | | | 895 | | | | | | 4,814 | | | | | | 4,364 | | |
Legal settlements and loss contingencies
|
| | | | — | | | | | | — | | | | | | 8,000 | | | | | | — | | |
Total operating expenses
|
| | | | 16,349 | | | | | | 11,440 | | | | | | 61,616 | | | | | | 35,453 | | |
Operating income
|
| | | $ | 9,932 | | | | | $ | 5,939 | | | | | $ | 23,489 | | | | | $ | 8,950 | | |
Financial income, net
|
| | | | 403 | | | | | | 278 | | | | | | 136 | | | | | | 849 | | |
Income before taxes
|
| | | $ | 10,335 | | | | | $ | 6,217 | | | | | $ | 23,625 | | | | | $ | 9,799 | | |
Income tax
|
| | | | 177 | | | | | | (149) | | | | | | 1,260 | | | | | | 980 | | |
Net income
|
| | | $ | 10,158 | | | | | $ | 6,366 | | | | | $ | 22,365 | | | | | $ | 8,819 | | |
Net loss (income) attributable to non-controlling interests
|
| | | | (34) | | | | | | — | | | | | | 6 | | | | | | — | | |
Net income attributable to controlling interest
|
| | | $ | 10,124 | | | | | $ | 6,366 | | | | | $ | 22,371 | | | | | $ | 8,819 | | |
Net income per ordinary share: | | | | | | | | | | | | | | | | ||||||||||
Basic
|
| | | $ | 0.38 | | | | | $ | 0.22 | | | | | $ | 0.82 | | | | | $ | 0.29 | | |
Diluted
|
| | | $ | 0.28 | | | | | $ | 0.17 | | | | | $ | 0.62 | | | | | $ | 0.26 | | |
Weighted average number of ordinary shares: | | | | | | | | | | | | | | | | ||||||||||
Basic
|
| | | | 26,818,179 | | | | | | 26,497,050 | | | | | | 26,613,942 | | | | | | 26,283,548 | | |
Diluted
|
| | | | 35,457,601 | | | | | | 34,711,741 | | | | | | 35,006,644 | | | | | | 29,669,922 | | |
|
| | |
As of March 31,
|
| |
As of December 31,
|
| ||||||||||||
| | | | |
2018
|
| |
2017
|
| ||||||||||
| | |
(in thousands)
|
| |||||||||||||||
Consolidated Balance Sheet Data: | | | | | | | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | $ | 18,951 | | | | | $ | 24,721 | | | | | $ | 17,593 | | |
Working capital(1)
|
| | | | 58,057 | | | | | | 48,335 | | | | | | 23,694 | | |
Total assets
|
| | | | 85,067 | | | | | | 81,056 | | | | | | 39,442 | | |
Total liabilities
|
| | | | 27,491 | | | | | | 34,193 | | | | | | 16,923 | | |
Redeemable non-controlling interests
|
| | | | 2,252 | | | | | | 2,187 | | | | | | 3,066 | | |
Retained earnings
|
| | | | 43,030 | | | | | | 32,971 | | | | | | 10,819 | | |
Non-controlling interests
|
| | | | 1,441 | | | | | | 1,413 | | | | | | — | | |
Total shareholders’ equity
|
| | | | 55,324 | | | | | | 44,676 | | | | | | 19,453 | | |
| | |
Percent of Revenue
|
| |||||||||||||||||||||
| | |
Three months ended
March 31, |
| |
Years ended
December 31, |
| ||||||||||||||||||
Geographic region
|
| |
2019
(%) |
| |
2018
(%) |
| |
2018
(%) |
| |
2017
(%) |
| ||||||||||||
North America (excluding Mexico)(1)
|
| | | | 88 | | | | | | 89 | | | | | | 89 | | | | | | 83 | | |
Europe | | | | | 7 | | | | | | 8 | | | | | | 6 | | | | | | 9 | | |
Asia-Pacific | | | | | 3 | | | | | | 1 | | | | | | 3 | | | | | | 6 | | |
Other | | | | | 2 | | | | | | 2 | | | | | | 2 | | | | | | 2 | | |
Total
|
| | | | 100 | | | | | | 100 | | | | | | 100 | | | | | | 100 | | |
| | |
Three months ended March 31,
|
| |||||||||||||||||||||
| | | | |
2018
|
| |||||||||||||||||||
| | |
($)
|
| |
(%)
|
| |
($)
|
| |
(%)
|
| ||||||||||||
| | |
(in thousands)
|
| |||||||||||||||||||||
Revenues | | | | | 30,552 | | | | | | 100 | | | | | | 20,911 | | | | | | 100 | | |
Cost of revenues
|
| | | | 4,271 | | | | | | 14 | | | | | | 3,532 | | | | | | 17 | | |
Gross profit
|
| | | | 26,281 | | | | | | 86 | | | | | | 17,379 | | | | | | 83 | | |
Operating expenses: | | | | | | ||||||||||||||||||||
Research and development
|
| | | | 1,199 | | | | | | 4 | | | | | | 880 | | | | | | 4 | | |
Sales and marketing
|
| | | | 14,097 | | | | | | 46 | | | | | | 9,665 | | | | | | 46 | | |
General and administrative
|
| | | | 1,053 | | | | | | 3 | | | | | | 895 | | | | | | 5 | | |
Total operating expenses
|
| | | | 16,349 | | | | | | 53 | | | | | | 11,440 | | | | | | 55 | | |
Income from operations
|
| | | | 9,932 | | | | | | 33 | | | | | | 5,939 | | | | | | 28 | | |
Financial income, net
|
| | | | 403 | | | | | | 1 | | | | | | 278 | | | | | | 1 | | |
Income before taxes
|
| | | | 10,335 | | | | | | 34 | | | | | | 6,217 | | | | | | 29 | | |
Income tax (tax benefit)
|
| | | | 177 | | | | | | 1 | | | | | | (149) | | | | | | (1) | | |
Net income
|
| | | | 10,158 | | | | | | 33 | | | | | | 6,366 | | | | | | 30 | | |
Net income attributable to non-controlling interests
|
| | | | 34 | | | | | | 0 | | | | | | — | | | | | | — | | |
Net income attributable to controlling interest
|
| | | | 10,124 | | | | | | 33 | | | | | | 6,366 | | | | | | 30 | | |
| | |
Years ended December 31,
|
| |||||||||||||||||||||
| | | | |
2017
|
| |||||||||||||||||||
| | |
($)
|
| |
(%)
|
| |
($)
|
| |
(%)
|
| ||||||||||||
| | |
(in thousands)
|
| |||||||||||||||||||||
Revenues | | | | | 100,162 | | | | | | 100 | | | | | | 53,456 | | | | | | 100 | | |
Cost of revenues
|
| | | | 15,057 | | | | | | 15 | | | | | | 9,053 | | | | | | 17 | | |
Gross profit
|
| | | | 85,105 | | | | | | 85 | | | | | | 44,403 | | | | | | 83 | | |
Operating expenses: | | | | | | ||||||||||||||||||||
Research and development
|
| | | | 4,180 | | | | | | 4 | | | | | | 2,575 | | | | | | 5 | | |
Sales and marketing
|
| | | | 44,622 | | | | | | 45 | | | | | | 28,514 | | | | | | 53 | | |
General and administrative
|
| | | | 4,814 | | | | | | 5 | | | | | | 4,364 | | | | | | 8 | | |
Legal settlements and loss contingencies
|
| | | | 8,000 | | | | | | 8 | | | | | | — | | | | | | — | | |
Total operating expenses
|
| | | | 61,616 | | | | | | 62 | | | | | | 35,453 | | | | | | 66 | | |
Income from operations
|
| | | | 23,489 | | | | | | 23 | | | | | | 8,950 | | | | | | 17 | | |
Financial income, net
|
| | | | 136 | | | | | | 1 | | | | | | 849 | | | | | | 2 | | |
Income before taxes
|
| | | | 23,625 | | | | | | 24 | | | | | | 9,799 | | | | | | 18 | | |
Income tax
|
| | | | 1,260 | | | | | | (2) | | | | | | 980 | | | | | | (2) | | |
Net income
|
| | | | 22,365 | | | | | | 22 | | | | | | 8,819 | | | | | | 16 | | |
Net loss attributable to non-controlling interests
|
| | | | 6 | | | | | | 0 | | | | | | — | | | | | | — | | |
Net income attributable to controlling interest
|
| | | | 22,371 | | | | | | 22 | | | | | | 8,819 | | | | | | 16 | | |
| | |
For the three months ended,
|
| | |||||||||||||||||||||||||||||||||||||||||||||||
| | |
2019
|
| |
2018
|
| |
2017
|
| ||||||||||||||||||||||||||||||||||||||||||
| | |
Mar. 31
|
| |
Dec. 31
|
| |
Sep. 30
|
| |
Jun. 30
|
| |
Mar. 31
|
| |
Dec. 31
|
| |
Sep. 30
|
| |
Jun. 30
|
| | ||||||||||||||||||||||||||
| | |
(unaudited)
(in thousands) |
| | |||||||||||||||||||||||||||||||||||||||||||||||
Revenues | | | | $ | 30,552 | | | | | $ | 28,783 | | | | | $ | 25,418 | | | | | $ | 25,050 | | | | | $ | 20,911 | | | | | $ | 19,807 | | | | | $ | 14,293 | | | | | $ | 13,877 | | | | ||
Cost of revenues
|
| | | | 4,271 | | | | | | 3,939 | | | | | | 3,669 | | | | | | 3,917 | | | | | | 3,532 | | | | | | 3,556 | | | | | | 2,075 | | | | | | 2,327 | | | | ||
Gross profit
|
| | | | 26,281 | | | | | | 24,844 | | | | | | 21,749 | | | | | | 21,133 | | | | | | 17,379 | | | | | | 16,251 | | | | | | 12,218 | | | | | | 11,550 | | | | ||
Operating expenses: | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||
Research and development
|
| | | | 1,199 | | | | | | 1,354 | | | | | | 1,005 | | | | | | 941 | | | | | | 880 | | | | | | 774 | | | | | | 674 | | | | | | 510 | | | | ||
Sales and marketing
|
| | | | 14,097 | | | | | | 12,521 | | | | | | 11,106 | | | | | | 11,330 | | | | | | 9,665 | | | | | | 10,434 | | | | | | 7,491 | | | | | | 6,734 | | | | ||
General and administrative
|
| | | | 1,053 | | | | | | 1,656 | | | | | | 1,244 | | | | | | 1,019 | | | | | | 895 | | | | | | 1,322 | | | | | | 1,223 | | | | | | 1,118 | | | | ||
Legal settlements and loss contingencies
|
| | | | — | | | | | | 8,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | ||
Total operating expenses
|
| | | | 16,349 | | | | | | 23,531 | | | | | | 13,355 | | | | | | 13,290 | | | | | | 11,440 | | | | | | 12,530 | | | | | | 9,388 | | | | | | 8,362 | | | | ||
Income (loss) from operations
|
| | | | 9,932 | | | | | | 1,313 | | | | | | 8,394 | | | | | | 7,843 | | | | | | 5,939 | | | | | | 3,721 | | | | | | 2,830 | | | | | | 3,188 | | | | ||
Financial income (expenses), net
|
| | | | 403 | | | | | | (487) | | | | | | 415 | | | | | | (70) | | | | | | 278 | | | | | | 218 | | | | | | 221 | | | | | | 247 | | | | ||
Income (loss) before
taxes |
| | | | 10,335 | | | | | | 826 | | | | | | 8,809 | | | | | | 7,773 | | | | | | 6,217 | | | | | | 3,939 | | | | | | 3,051 | | | | | | 3,435 | | | | ||
Income tax (tax benefit)
|
| | | | 177 | | | | | | 1,045 | | | | | | 171 | | | | | | 193 | | | | | | (149) | | | | | | 620 | | | | | | 144 | | | | | | 123 | | | | ||
Net income (loss)
|
| | | $ | 10,158 | | | | | $ | (219) | | | | | $ | 8,638 | | | | | $ | 7,580 | | | | | $ | 6,366 | | | | | $ | 3,319 | | | | | $ | 2,907 | | | | | $ | 3,312 | | | |
| | |
Three months ended
March 31, |
| |
Years ended
December 31, |
| ||||||||||||||||||
| | | | |
2018
|
| |
2018
|
| |
2017
|
| |||||||||||||
| | |
(in thousands)
|
| |||||||||||||||||||||
Net cash provided by (used in): | | | | | | | | | | | | | | | | | | | | | | | | | |
Operating activities
|
| | | $ | 2,771 | | | | | $ | 7,397 | | | | | $ | 36,886 | | | | | $ | 14,609 | | |
Investing activities
|
| | | | (8,693) | | | | | | (1,993) | | | | | | (29,739) | | | | | | (5,684) | | |
Financing activities
|
| | | | 122 | | | | | | 150 | | | | | | 186 | | | | | | 1,785 | | |
Effects of exchange rate changes on cash
|
| | | | 30 | | | | | | (11) | | | | | | (205) | | | | | | 187 | | |
Net increase (decrease) in cash and cash equivalents
|
| | | $ | (5,770) | | | | | $ | 5,543 | | | | | $ | 7,128 | | | | | $ | 10,897 | | |
| | | | | | | | |
Payments Due by Period
|
| |||||||||||||||||||||
| | |
Total
|
| |
Less than
1 year |
| |
1 – 3 years
|
| |
3 – 5 years
|
| |
More than
5 years |
| |||||||||||||||
| | |
($) (in thousands)
|
| |||||||||||||||||||||||||||
Operating lease (including imputed
interest) |
| | | | 1,800 | | | | | | 508 | | | | | | 1,221 | | | | | | 71 | | | | | | — | | |
Subcontracting agreement
|
| | | | 2,400 | | | | | | 2,400 | | | | | | — | | | | | | — | | | | | | — | | |
| | |
For the three months ended
March 31, |
| |
For the year ended
December 31, |
|
| | | | |
2018
|
| |
Dividend yield
|
| |
0%
|
| |
0%
|
|
Expected volatility
|
| |
51.91%
|
| |
51.20%
|
|
Risk-free interest rate
|
| |
2.56 – 2.60%
|
| |
2.96%
|
|
Early exercise multiple
|
| |
150% – 250%
|
| |
150% – 250%
|
|
Contractual term
|
| |
7 years
|
| |
7 years
|
|
Grant Date
|
| |
Number of
Options Granted |
| |
Exercise
Price |
| |
Fair Value
per Share |
| |
Fair Value
per Option |
| ||||||||||||
| | | | 2,598,619 | | | | | $ | 0.56 | | | | | $ | 0.58 | | | | | $ | 0.26 | | | |
| | | | 21,468 | | | | | $ | 0.56 | | | | | $ | 3.12 | | | | | $ | 2.56 | | | |
| | | | 35,780 | | | | | $ | 0.56 | | | | | $ | 4.11 | | | | | $ | 3.57 | | | |
| | | | 3,578 | | | | | $ | 0.56 | | | | | $ | 4.86 | | | | | $ | 4.33 | | | |
| | | | 354,402 | | | | | $ | 6.32 | | | | | $ | 6.32 | | | | | $ | 2.54 | | | |
| | | | 169,956 | | | | | $ | 7.49 | | | | | $ | 7.49 | | | | | $ | 2.09 | | | |
| | | | 305,919 | | | | | $ | 7.49 | | | | | $ | 7.49 | | | | | $ | 2.09 | | | |
| | | | 30,413 | | | | | $ | 10.23 | | | | | $ | 10.23 | | | | | $ | 2.82 | | | |
| | | | 67,982 | | | | | $ | 10.23 | | | | | $ | 10.23 | | | | | $ | 2.82 | | | |
| | | | 14,313 | | | | | $ | 10.23 | | | | | $ | 10.23 | | | | | $ | 2.82 | | |
Product Platform |
| |
Energy
Source(s) |
| |
Year
Introduced |
| |
Handpiece(s)
|
| |
Primary (not Exclusive) Applications*
|
|
BodyTite
|
| |
Bipolar RF
|
| |
2010
|
| |
BodyTite
FaceTite NeckTite AccuTite |
| |
Body Contouring (MI)
Face Contouring (MI) Neck Contouring (MI) Face/Body Contouring (MI) |
|
Optimas
|
| |
Laser
Bipolar RF IPL |
| |
2016
|
| |
Fractora
Forma Lumecca DiolazeXL Vasculaze Morpheus8 |
| |
Skin Rejuvenation (MI)
Skin Rejuvenation (NI) Skin Rejuvenation & Pigmentation (NI) Hair Removal (NI) Vascular Lesion (NI) Facial Wrinkles and Texture (MI) |
|
Votiva
|
| |
Bipolar RF
|
| |
2017
|
| |
FractoraV
FormaV |
| |
Women’s Health (MI)
Woman’s Health (NI) |
|
Product Platform |
| |
Energy
Source(s) |
| |
Year
Introduced |
| |
Handpiece(s)
|
| |
Primary (not Exclusive) Applications*
|
|
Contoura
|
| |
Bipolar RF
|
| |
2017
|
| |
BodyFX
MiniFX Plus |
| |
Body Contouring (NI)
Face/Neck Contouring (NI) Skin Tightening (NI) |
|
Triton
|
| |
Laser
|
| |
2018
|
| |
Triton Duo Light
Triton Duo Dark |
| |
Hair Removal (NI)
Hair Removal (NI) |
|
EmbraceRF
|
| |
Bipolar RF
|
| |
2018
|
| |
FaceTite
Morpheus8 AccuTite |
| |
Face Remodeling (MI)
Facial Wrinkles and Texture (MI) Face/Body Contouring (MI) |
|
Product Platform
|
| |
Energy Source
|
| |
Handpiece
|
| |
FDA 510(k) Clearance and Cleared Indications
|
|
BodyTite
|
| |
Radiofrequency
(RF) |
| |
BodyTite 40W
|
| |
K171593 (10/10/2017)
The BodyTite product platform with the BodyTite 40W handpiece is indicated for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. |
|
|
BodyTite 20W
|
| | K163190 (12/12/2016) The BodyTite product platform with the BodyTite 20W handpiece is indicated for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. |
| |||||
| | | | | |
FaceTite
|
| | K151793 (02/19/2016) The BodyTite product platform with the FaceTite handpiece is indicated for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. |
|
| | | | | |
Fractora
with 60 Pin Tip |
| | K102461 (06/02/2011) The BodyTite product platform with the Fractora with a 60 pin tip handpiece is indicated for use in dermatological procedures requiring ablation and resurfacing of the skin. |
|
Product Platform
|
| |
Energy Source
|
| |
Handpiece
|
| |
FDA 510(k) Clearance and Cleared Indications
|
|
| | | | | |
Fractora
with 24 Pin Tip |
| | K151273 (01/04/2016) The BodyTite product platform with the Fractora with a 24 pin tip handpiece is indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. |
|
| | | | | |
Morpheus8
|
| | K180189 (06/01/2018) The BodyTite product platform with the Morpheus8 handpiece is indicated for use in dermatological and general surgical procedures for electrocoagulation and homeostasis. |
|
| | | | | |
AccuTite
|
| | K182325 (08/27/2018) The BodyTite product platform with the AccuTite handpiece is indicated for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. |
|
Optimas
|
| |
RF
|
| |
Fractora
with 60 Pin Tip |
| |
K102461 (06/02/2011)
The Optimas product platform with the Fractora with a 60 pin tip handpiece is indicated for use in dermatological procedures requiring ablation and resurfacing of the skin. |
|
|
Fractora
with 24 Pin Tip |
| | K151273 (01/04/2016) The Optimas product platform with the Fractora with a 24 pin tip handpiece is indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. |
| |||||
| RF | | |
Forma
|
| | K172302 (12/08/2017) The Optimas product platform with the Forma handpiece is indicated for the temporary relief of minor muscle aches and pain, temporary relief of muscle spasm, and temporary improvement of local blood circulation. |
| ||
| | | Intense Pulsed Light (IPL) |
| |
Lumecca 515
Lumecca 580 |
| |
K123860 (04/02/2013)
The Optimas product platform with the Lumecca 515 and Lumecca 580 handpieces are indicated for: •
the treatment of benign pigmented epidermal lesions, including dyschrornia, hyperpigmentation, melasma, ephelides (freckles); and
|
|
Product Platform
|
| |
Energy Source
|
| |
Handpiece
|
| |
FDA 510(k) Clearance and Cleared Indications
|
|
| | | | | | | | |
•
the treatment of benign cutaneous vascular lesions, including port wine stains, facial truncal and leg telangiectasias, rosacea, erythema of rosacea, angiomas and spider angiomas, poikilodenna of civatte, superficial leg veins and venous malformations.
|
|
| | | Laser | | |
DiolazeXL
|
| | K170738 (08/07/2017) The Optimas product platform with the DiolazeXL handpiece is indicated for hair removal and permanent hair reduction. |
|
| | | Laser | | |
Vasculaze
|
| | K173677 (02/23/2018) The Optimas product platform with the Vasculaze handpiece is indicated for the treatment of vascular lesions, including angiomas, hemangiomas, telangiectasia, port wine stains, leg veins and other benign vascular lesions. |
|
Votiva
|
| |
RF
|
| |
FractoraV
|
| |
K151273 (01/04/2016)
The Votiva product platform with the FractoraV handpiece is indicated for the use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. |
|
|
FormaV
|
| | K153568 (07/12/2016)* The Votiva product platform with the FormaV handpiece is indicated for the temporary relief of minor muscle aches and pain, temporary relief of muscle spasm, and temporary improvement of local blood circulation. |
| |||||
Contoura
|
| | RF | | |
BodyFX
|
| |
K131362 (10/08/2013)
The Contoura product platform with the BodyFX handpiece is indicated for the treatment of: •
relief of minor muscle aches and pains, muscle spasms, temporary improvement of blood circulation; and
•
temporary reduction in the appearance of cellulite.
|
|
Product Platform
|
| |
Energy Source
|
| |
Handpiece
|
| |
FDA 510(k) Clearance and Cleared Indications
|
|
| | | | | |
MiniFX
|
| |
K160329 (08/19/2016)
The Contoura product platform with the MiniFX handpiece is indicated for the treatment of: •
relief of minor muscle aches and pain, muscle spasms, temporary improvement of local blood circulation; and
•
temporary reduction in the appearance of cellulite.
|
|
| | | | | |
Plus
|
| | K172302 (12/08/2017) The Contoura product platform with the Plus handpiece is indicated for the temporary relief of minor muscle aches and pain, temporary relief of muscle spasms, and temporary improvement of local blood circulation. |
|
Triton
|
| |
Laser
|
| |
Triton Duo
Light |
| |
K180719 (06/14/2018)
The Triton product platform with the Triton Duo Light and Triton Duo Dark handpieces are indicated for hair removal and permanent hair reduction. |
|
| Triton Duo Dark |
| ||||||||
EmbraceRF
|
| |
RF
|
| |
FaceTite
|
| |
K151793 (02/19/2016)
The EmbraceRF product platform with the FaceTite handpiece is indicated for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. |
|
|
Morpheus8
|
| | K180189 (06/01/2018) The EmbraceRF product platform with the Morpheus8 handpiece is indicated for the use in dermatological and general surgical procedures for electrocoagulation and homeostasis. |
| |||||
| | | | | |
AccuTite
|
| | K182325 (08/27/2018) The EmbraceRF product platform with the AccuTite handpiece is indicated for the use in dermatological and general surgical procedures for electrocoagulation and homeostasis. |
|
Name
|
| |
Age
|
| |
Position
|
|
Executive Officers | | | | | | | |
Moshe Mizrahy | | |
66
|
| | Chief Executive Officer and Chairman of Board of Directors | |
Yair Malca | | |
41
|
| | Chief Financial Officer | |
Dr. Michael Kreindel | | |
52
|
| | Chief Technology Officer and Director | |
Shakil Lakhani | | |
35
|
| | President, North America | |
Dr. Spero Theodorou, M.D.
|
| |
47
|
| | Chief Medical Officer | |
Non-Employee Directors | | | | | | | |
Dr. Hadar Ron, M.D.(1)(2) | | |
60
|
| | Director | |
Bruce Mann(1)(2) | | |
84
|
| | Director | |
Dr. Michael Anghel(1)(2) | | |
80
|
| | Director | |
Name
|
| |
Number of
Options |
| |
Exercise
Price |
| |
Date of
Grant |
| |
Expiration
Date |
| | ||||||||
Yair Malca
|
| | | | 125,230 | | | | | $ | 0.56 | | | |
6/1/2017
|
| |
6/1/2024
|
| | ||
Shakil Lakhani
|
| | | | 894,500 | | | | | $ | 0.56 | | | |
2/16/2017
|
| |
2/16/2024
|
| | ||
| | | | | 195,896 | | | | | $ | 0.56 | | | |
6/1/2017
|
| |
6/1/2024
|
| | ||
Dr. Spero Theodorou
|
| | | | 4,473 | | | | | $ | 0.56 | | | |
4/15/2010
|
| |
3/31/2022
|
| | ||
| | | | | 125,230 | | | | | $ | 0.56 | | | |
1/26/2011
|
| |
3/31/2022
|
| | ||
| | | | | 26,835 | | | | | $ | 0.56 | | | |
4/4/2012
|
| |
4/4/2024
|
| | ||
| | | | | 89,450 | | | | | $ | 0.56 | | | |
8/29/2016
|
| |
8/29/2023
|
| | | |
| | | | | 412,365 | | | | | $ | 0.56 | | | |
6/1/2017
|
| |
6/1/2024
|
| | ||
| | | | | 27,730 | | | | | $ | 0.56 | | | |
2/16/2017
|
| |
2/16/2024
|
| |
Name
|
| |
Number of
Options |
| |
Exercise
Price |
| |
Date of
Grant |
| |
Expiration
Date |
| ||||||
Yair Malca | | | | | 35,780 | | | | | $ | 6.32 | | | |
9/17/2018
|
| |
9/17/2025
|
|
| | | | | 35,780 | | | | | $ | 7.49 | | | |
1/07/2019
|
| |
9/17/2026
|
|
Dr. Spero Theodorou | | | | | 53,670 | | | | | $ | 6.32 | | | |
9/17/2018
|
| |
9/17/2025
|
|
| | | | | 89,450 | | | | | $ | 7.49 | | | |
1/07/2019
|
| |
1/07/2026
|
|
Shakil Lakhani | | | | | 89,450 | | | | | $ | 7.49 | | | |
1/07/2019
|
| |
1/07/2026
|
|
| | |
Beneficial Ownership
|
| |||||||||||||||
Name of Beneficial Owner:
|
| |
Number of
Ordinary Shares |
| |
Percent of
Ordinary Shares Before the Offering |
| |
Percent of Ordinary
Shares After the Offering |
| |||||||||
5% or more Beneficial Owners | | | | | | | | | | | | | | | | | | | |
Israel Healthcare Ventures 2 LP Incorporated(1)
|
| | | | 4,667,754 | | | | | | 15.8% | | | | | | 13.5% | | |
SpaMedica International SRL(2)
|
| | | | 4,436,720 | | | | | | 15.1% | | | | | | 12.9% | | |
Directors, Director Nominees and Named Executive Officers
|
| | | | |||||||||||||||
Dr. Michael Kreindel(3)
|
| | | | 5,188,100 | | | | | | 17.6% | | | | | | 15.1% | | |
Moshe Mizrahy
|
| | | | 6,069,278 | | | | | | 20.6% | | | | | | 17.6% | | |
Dr. Hadar Ron(4)
|
| | | | 89,450 | | | | | | * | | | | | | * | | |
Bruce Mann(3)
|
| | | | 26,835 | | | | | | * | | | | | | * | | |
Dr. Michael Anghel
|
| | | | — | | | | | | — | | | | | | — | | |
Yair Malca(5)
|
| | | | 169,955 | | | | | | * | | | | | | * | | |
Shakil Lakhani(5)
|
| | | | 1,135,120 | | | | | | 3.8% | | | | | | 3.3% | | |
Dr. Spero Theodorou(5)
|
| | | | 771,060 | | | | | | 2.6% | | | | | | 2.2% | | |
Total for all directors, director nominees and executive officers as a group (8 persons)
|
| | |
|
13,449,798
|
| | | |
|
45.7%
|
| | | |
|
39.0%
|
| |
|
Approximate Number of Ordinary Shares
|
| |
Description
|
|
5,000,000 | | | After the date of this prospectus, freely tradeable ordinary shares sold in this offering (or 5,750,000 assuming full exercise of the underwriters option to purchase additional shares). | |
26,973,572 | | | After 180 days from the date of this prospectus, except as otherwise discussed below, the lock-up period will expire, and these additional ordinary shares will be saleable, subject, in some cases, to holding periods and volume limitations. | |
Underwriters
|
| |
Number of
Ordinary Shares |
| |||
Barclays Capital Inc.
|
| | | | 2,062,500 | | |
UBS Securities LLC
|
| | | | 1,562,500 | | |
Canaccord Genuity LLC
|
| | | | 875,000 | | |
Robert W. Baird & Co. Incorporated
|
| | | | 500,000 | | |
Total
|
| | | | 5,000,000 | | |
| | |
No
Exercise |
| |
Full
Exercise |
| ||||||
Per ordinary share
|
| | | $ | 0.98 | | | | | $ | 0.98 | | |
Total
|
| | | $ | 4,900,000 | | | | | $ | 5,635,000 | | |
| | |
Amount
|
| |||
SEC registration fee
|
| | | $ | 11,150 | | |
FINRA filing fees
|
| | | | 14,300 | | |
Nasdaq Global Select Market listing fee
|
| | | | 150,000 | | |
Printing and engraving expenses
|
| | | | 185,000 | | |
Legal fees and expenses
|
| | | | 1,238,000 | | |
Accounting fees and expenses
|
| | | | 200,000 | | |
Transfer agent and registrar fees
|
| | | | 75,000 | | |
Miscellaneous
|
| | | | 1,550 | | |
Total
|
| | | $ | 1,875,000 | | |
| | |
Page
|
| |||
CONSOLIDATED FINANCIAL STATEMENTS: | | | | | | | |
| | | | F-2 | | | |
| | | | F-3 | | | |
| | | | F-4 | | | |
| | | | F-5 | | | |
| | | | F-6 | | | |
| | | | F-7 | | | |
| | | | F-8 | | | |
Unaudited Condensed Consolidated Financial Statements: | | | | | | | |
| | | | F-34 | | | |
| | | | F-35 | | | |
| | | | F-36 | | | |
| | | | F-37 | | | |
| | | | F-38 | | | |
| | | | F-39 | | |
| Tel-Aviv, Israel March 13, 2019, except for the effects of the stock split discussed in Note 14 to the financial statements, as to which the date is July 26, 2019 |
| | /s/ Kesselman & Kesselman Certified Public Accountants (lsr.) A member of PricewaterhouseCoopers International Limited |
|
| | | | ||||||||||
| | | | |
2017
|
| |||||||
Assets | | | | | | | | | | | | | |
CURRENT ASSETS: | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | $ | 24,721 | | | | | $ | 17,593 | | |
Marketable securities
|
| | | | 26,532 | | | | | | 7,447 | | |
Short-term bank deposits
|
| | | | 10,045 | | | | | | — | | |
Accounts receivable, net of allowance for doubtful accounts
|
| | | | 7,008 | | | | | | 5,763 | | |
Other receivables
|
| | | | 2,495 | | | | | | 1,311 | | |
Inventories
|
| | | | 6,963 | | | | | | 5,035 | | |
TOTAL CURRENT ASSETS
|
| | | $ | 77,764 | | | | | $ | 37,149 | | |
NON-CURRENT ASSETS: | | | | | | | | | | | | | |
Accounts receivable
|
| | | $ | 544 | | | | | $ | 1,137 | | |
Deferred offering costs
|
| | | | 895 | | | | | | — | | |
Deferred income taxes, net
|
| | | | 1,309 | | | | | | 810 | | |
Property and equipment, net
|
| | | | 544 | | | | | | 346 | | |
TOTAL NON-CURRENT ASSETS
|
| | | | 3,292 | | | | | | 2,293 | | |
TOTAL ASSETS
|
| | | $ | 81,056 | | | | | $ | 39,442 | | |
Liabilities and shareholders’ equity | | | | | | | | | | | | | |
CURRENT LIABILITIES: | | | | | | | | | | | | | |
Accounts payable
|
| | | $ | 4,509 | | | | | $ | 3,064 | | |
Contract liabilities
|
| | | | 5,755 | | | | | | 1,134 | | |
Other liabilities
|
| | | | 9,165 | | | | | | 7,257 | | |
Accrued contingencies
|
| | | | 10,000 | | | | | | 2,000 | | |
TOTAL CURRENT LIABILITIES
|
| | | $ | 29,429 | | | | | $ | 13,455 | | |
NON-CURRENT LIABILITIES: | | | | | | | | | | | | | |
Contract liabilities
|
| | | $ | 3,982 | | | | | $ | 3,362 | | |
Other liabilities
|
| | | | 771 | | | | | | — | | |
Deferred income taxes, net
|
| | | | 11 | | | | | | 106 | | |
TOTAL NON-CURRENT LIABILITIES
|
| | | | 4,764 | | | | | | 3,468 | | |
TOTAL LIABILITIES
|
| | | $ | 34,193 | | | | | $ | 16,923 | | |
COMMITMENTS AND CONTINGENCIES (Note 9)
|
| | | | | | | | | | | | |
REDEEMABLE NON-CONTROLLING INTEREST
|
| | | $ | 2,187 | | | | | $ | 3,066 | | |
SHAREHOLDERS’ EQUITY: | | | | | | | | | | | | | |
Ordinary shares, NIS 0.01 par value, – authorized: 100,000,000 shares; issued and outstanding: 26,682,413 and 26,350,484 shares at December 31, 2018 and 2017, respectively
|
| | | $ | 74 | | | | | $ | 74 | | |
Additional paid-in capital
|
| | | | 10,152 | | | | | | 8,019 | | |
Retained earnings
|
| | | | 32,971 | | | | | | 10,819 | | |
Accumulated other comprehensive income
|
| | | | 66 | | | | | | 541 | | |
InMode Ltd. shareholders’ equity
|
| | | | 43,263 | | | | | | 19,453 | | |
Non-controlling interests
|
| | | | 1,413 | | | | | | — | | |
TOTAL SHAREHOLDERS’ EQUITY
|
| | | | 44,676 | | | | | | 19,453 | | |
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
|
| | | $ | 81,056 | | | | | $ | 39,442 | | |
|
| | |
Year ended December 31,
|
| |||||||||
| | | | |
2017
|
| |||||||
REVENUES
|
| | | $ | 100,162 | | | | | $ | 53,456 | | |
COST OF REVENUES
|
| | | | 15,057 | | | | | | 9,053 | | |
GROSS PROFIT
|
| | | | 85,105 | | | | | | 44,403 | | |
OPERATING EXPENSES: | | | | | | | | | | | | | |
Research and development
|
| | | | 4,180 | | | | | | 2,575 | | |
Sales and marketing
|
| | | | 44,622 | | | | | | 28,514 | | |
General and administrative
|
| | | | 4,814 | | | | | | 4,364 | | |
Legal settlements and loss contingencies
|
| | | | 8,000 | | | | | | — | | |
TOTAL OPERATING EXPENSES
|
| | | | 61,616 | | | | | | 35,453 | | |
INCOME FROM OPERATIONS
|
| | | | 23,489 | | | | | | 8,950 | | |
Finance income, net
|
| | | | 136 | | | | | | 849 | | |
INCOME BEFORE TAXES
|
| | | | 23,625 | | | | | | 9,799 | | |
INCOME TAX
|
| | | | 1,260 | | | | | | 980 | | |
NET INCOME
|
| | | | 22,365 | | | | | | 8,819 | | |
Net loss attributable to non-controlling interests
|
| | | | 6 | | | | | | — | | |
NET INCOME ATTRIBUTABLE TO CONTROLLING INTEREST
|
| | | $ | 22,371 | | | | | $ | 8,819 | | |
NET INCOME PER SHARE: | | | | | | | | | | | | | |
Basic
|
| | | $ | 0.82 | | | | | $ | 0.29 | | |
Diluted
|
| | | $ | 0.62 | | | | | $ | 0.26 | | |
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED
IN COMPUTATION OF NET INCOME PER SHARE |
| | | | | | | | | | | | |
Basic
|
| | | | 26,613,942 | | | | | | 26,283,548 | | |
Diluted
|
| | | | 35,006,644 | | | | | | 29,669,922 | | |
| | |
Year ended December 31,
|
| |||||||||
| | | | |
2017
|
| |||||||
NET INCOME
|
| | | $ | 22,365 | | | | | $ | 8,819 | | |
OTHER COMPREHENSIVE INCOME: | | | | | | | | | | | | | |
Change in foreign currency translation adjustment
|
| | | | (153) | | | | | | 73 | | |
Change in net unrealized gains of marketable securities, net of tax
|
| | | | (1) | | | | | | 302 | | |
TOTAL COMPREHENSIVE INCOME, net
|
| | | | 22,211 | | | | | | 9,194 | | |
Comprehensive loss attributable to non-controlling interests
|
| | | | 1 | | | | | | — | | |
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO CONTROLLING INTEREST
|
| | | $ | 22,212 | | | | | $ | 9,194 | | |
| | |
InMode Ltd. Shareholders’ Equity
|
| |
Non-controlling
Interests |
| |
Total
|
| |||||||||||||||||||||||||||||||||
| | |
Ordinary Shares
|
| |
Additional
paid-in capital |
| |
Retained
earnings |
| |
Accumulated
other comprehensive income |
| ||||||||||||||||||||||||||||||
| | |
Number of
shares issued |
| |
Amount
|
| ||||||||||||||||||||||||||||||||||||
BALANCE AT JANUARY 1,
2017 |
| | | | 26,250,393 | | | | | | 74 | | | | | $ | 5,527 | | | | | $ | 3,154 | | | | | $ | 166 | | | | | | — | | | | | $ | 8,921 | | |
CHANGES DURING 2017: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Net income
|
| | | | — | | | | | | — | | | | | | — | | | | | | 8,819 | | | | | | — | | | | | | — | | | | | | 8,819 | | |
Other comprehensive income, net
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 375 | | | | | | — | | | | | | 375 | | |
Share-based compensation
|
| | | | — | | | | | | — | | | | | | 2,436 | | | | | | — | | | | | | — | | | | | | — | | | | | | 2,436 | | |
Adjustment to redemption value of redeemable non-controlling interest
|
| | | | — | | | | | | — | | | | | | — | | | | | | (1,154) | | | | | | — | | | | | | — | | | | | | (1,154) | | |
Exercise of options
|
| | | | 100,091 | | | | | | * | | | | | | 56 | | | | | | — | | | | | | — | | | | | | — | | | | | | 56 | | |
BALANCE AT DECEMBER 31,
2017 |
| | | | 26,350,484 | | | | | | 74 | | | | | $ | 8,019 | | | | | $ | 10,819 | | | | | $ | 541 | | | | | | — | | | | | $ | 19,453 | | |
BALANCE AS OF JANUARY 1,
2018, as previously reported |
| | | | 26,350,484 | | | | | | 74 | | | | | $ | 8,019 | | | | | $ | 10,819 | | | | | $ | 541 | | | | | | — | | | | | $ | 19,453 | | |
Impact of adoption of ASU 2016-01 (see note 2w(1))
|
| | | | — | | | | | | — | | | | | | — | | | | | | 316 | | | | | | (316) | | | | | | — | | | | | | — | | |
BALANCE AS OF JANUARY 1,
2018, as adjusted |
| | | | 26,350,484 | | | | | | 74 | | | | | $ | 8,019 | | | | | $ | 11,135 | | | | | $ | 225 | | | | | | — | | | | | $ | 19,453 | | |
CHANGES DURING 2018: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Net income
|
| | | | — | | | | | | — | | | | | | — | | | | | | 22,371 | | | | | | — | | | | | | (6) | | | | | | 22,365 | | |
Other comprehensive income, net
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (159) | | | | | | 5 | | | | | | (154) | | |
Share-based compensation
|
| | | | — | | | | | | — | | | | | | 1,947 | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,947 | | |
Adjustment to redemption value of redeemable non-controlling interest
|
| | | | — | | | | | | — | | | | | | — | | | | | | (535) | | | | | | — | | | | | | — | | | | | | (535) | | |
Waiver of redeemable non-controlling interests (see note 10b)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,414 | | | | | | 1,414 | | |
Exercise of options
|
| | | | 331,929 | | | | | | * | | | | | | 186 | | | | | | — | | | | | | — | | | | | | — | | | | | | 186 | | |
BALANCE AT DECEMBER 31,
2018 |
| | | | 26,682,413 | | | | | | 74 | | | | | $ | 10,152 | | | | | $ | 32,971 | | | | | $ | 66 | | | | | | 1,413 | | | | | $ | 44,676 | | |
| | |
Year ended December 31,
|
| |||||||||
| | | | |
2017
|
| |||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | | | | | | | | | | | | | |
Net income
|
| | | $ | 22,365 | | | | | $ | 8,819 | | |
Adjustments required to reconcile net income to net cash provided by operating activities:
|
| | | | | | | | | | | | |
Depreciation and amortization
|
| | | | 184 | | | | | | 204 | | |
Share-based compensation
|
| | | | 1,947 | | | | | | 2,436 | | |
Allowance for doubtful accounts expenses
|
| | | | (33) | | | | | | 186 | | |
Gains on marketable securities, net
|
| | | | (21) | | | | | | (1) | | |
Changes in fair value of marketable securities, net
|
| | | | 291 | | | | | | 29 | | |
Finance income
|
| | | | (45) | | | | | | — | | |
Provision for deferred income taxes, net
|
| | | | (592) | | | | | | (580) | | |
Change in accrued contingencies
|
| | | | 8,000 | | | | | | — | | |
Changes in operating assets and liabilities:
|
| | | | | | | | | | | | |
Increase in accounts receivable
|
| | | | (571) | | | | | | (2,699) | | |
Increase in other receivables
|
| | | | (1,171) | | | | | | (1,021) | | |
Increase in inventories
|
| | | | (1,891) | | | | | | (2,342) | | |
Increase in accounts payable
|
| | | | 541 | | | | | | 1,506 | | |
Increase in other liabilities
|
| | | | 2,631 | | | | | | 3,982 | | |
Increase in contract liabilities
|
| | | | 5,251 | | | | | | 4,090 | | |
Net cash provided by operating activities
|
| | | $ | 36,886 | | | | | $ | 14,609 | | |
CASH FLOWS FROM INVESTING ACTIVITIES: | | | | | | | | | | | | | |
Investment in short-term deposit
|
| | | $ | (10,000) | | | | | $ | — | | |
Purchase of fixed assets
|
| | | | (381) | | | | | | (189) | | |
Purchase of marketable securities
|
| | | | (38,346) | | | | | | (5,697) | | |
Proceeds from sale of marketable securities
|
| | | | 18,988 | | | | | | 202 | | |
Net cash used in investing activities
|
| | | $ | (29,739) | | | | | $ | (5,684) | | |
CASH FLOWS FROM FINANCING ACTIVITIES: | | | | | | | | | | | | | |
Transaction with redeemable non-controlling interest
|
| | | $ | — | | | | | $ | 1,729 | | |
Exercise of options
|
| | | | 186 | | | | | | 56 | | |
Net cash provided by financing activities
|
| | | | 186 | | | | | | 1,785 | | |
EFFECT OF EXCHANGE RATE CHANGES ON CASH
|
| | | | (205) | | | | | | 187 | | |
NET INCREASE IN CASH AND CASH EQUIVALENTS
|
| | | | 7,128 | | | | | | 10,897 | | |
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD
|
| | | | 17,593 | | | | | | 6,696 | | |
CASH AND CASH EQUIVALENTS AT END OF PERIOD
|
| | | $ | 24,721 | | | | | $ | 17,593 | | |
SUPPLEMENTAL DISCLOSURES OF CASH FLOWS INFORMATION: | | | | | | | | | | | | | |
Income taxes paid
|
| | | $ | 1,800 | | | | | $ | 737 | | |
Interest received
|
| | | $ | 662 | | | | | $ | 605 | | |
NON CASH FINANCING ACTIVITIES | | | | ||||||||||
Deferred offering costs in accounts payable
|
| | | $ | 895 | | | | | $ | — | | |
| Computers | | |
3 – 4 years
|
|
| Molds | | |
4 – 10 years
|
|
| Equipment and furniture | | |
10 – 17 years
|
|
| | | | ||||||||||
| | | | |
2017
|
| |||||||
Balance at beginning of year
|
| | | $ | 380 | | | | | $ | 355 | | |
Charged to expense
|
| | | | (1,009) | | | | | | (547) | | |
Costs incurred
|
| | | | 1,335 | | | | | | 572 | | |
Balance at end of year
|
| | | $ | 706 | | | | | $ | 380 | | |
| | | | ||||||||||
| | | | |
2017
|
| |||||||
Marketable equity securities
|
| | | $ | — | | | | | $ | 4,234 | | |
Government securities*
|
| | | | 21,932 | | | | | | — | | |
Corporate debt securities
|
| | | | 4,600 | | | | | | 2,655 | | |
Mutual funds
|
| | | | — | | | | | | 558 | | |
Total
|
| | | $ | 26,532 | | | | | $ | 7,447 | | |
| | | | ||||||||||||||||||||||
| | |
Fair
value |
| |
Cost or
amortized cost |
| |
Gross
unrealized holding loss |
| |
Gross
unrealized holding gains |
| ||||||||||||
Level 2 securities: | | | | | | ||||||||||||||||||||
Government securities
|
| | | $ | 21,932 | | | | | $ | 21,878 | | | | | $ | (3) | | | | | $ | 57 | | |
Corporate debt securities
|
| | | | 4,600 | | | | | | 4,606 | | | | | | (15) | | | | | | 9 | | |
Total
|
| | | $ | 26,532 | | | | | $ | 26,484 | | | | | $ | (18) | | | | | $ | 66 | | |
|
| | | | ||||||||||||||||||||||
| | |
Fair
value |
| |
Cost or
amortized cost |
| |
Gross
unrealized holding loss |
| |
Gross
unrealized holding gains |
| ||||||||||||
Level 1 securities: | | | | | | ||||||||||||||||||||
Marketable equity securities
|
| | | $ | 4,234 | | | | | $ | 3,832 | | | | | $ | (45) | | | | | $ | 447 | | |
Mutual funds
|
| | | | 558 | | | | | | 550 | | | | | | — | | | | | | 8 | | |
Level 2 securities: | | | | | | ||||||||||||||||||||
Corporate debt securities
|
| | | | 2,655 | | | | | | 2,604 | | | | | | (17) | | | | | | 68 | | |
Total
|
| | | $ | 7,447 | | | | | $ | 6,986 | | | | | $ | (62) | | | | | $ | 523 | | |
| | |
Market value
|
| |||||||||
| | | | ||||||||||
| | | | |
2017
|
| |||||||
Due within one year
|
| | | $ | 12,801 | | | | | $ | 200 | | |
1 to 2 years
|
| | | | 9,068 | | | | | | — | | |
2 to 3 years
|
| | | | 2,609 | | | | | | — | | |
3 to 4 years
|
| | | | 2,054 | | | | | | 169 | | |
4 to 5 years
|
| | | | — | | | | | | 820 | | |
More than 5 years
|
| | | | — | | | | | | 1,466 | | |
Total
|
| | | $ | 26,532 | | | | | $ | 2,655 | | |
| | | | ||||||||||
| | | | |
2017
|
| |||||||
Trade
|
| | | $ | 6,768 | | | | | $ | 6,759 | | |
Notes receivable
|
| | | | 1,138 | | | | | | 528 | | |
Less – allowance for doubtful debt
|
| | | | (354) | | | | | | (387) | | |
| | | | | 7,552 | | | | | | 6,900 | | |
Less – non-current accounts receivable
|
| | | | (544) | | | | | | (1,137) | | |
Total accounts receivable
|
| | | $ | 7,008 | | | | | $ | 5,763 | | |
| | | | ||||||||||
| | | | |
2017
|
| |||||||
Raw materials
|
| | | $ | 2,508 | | | | | $ | 2,407 | | |
Finished products
|
| | | | 4,455 | | | | | | 2,628 | | |
Total inventories
|
| | | $ | 6,963 | | | | | $ | 5,035 | | |
| | | | ||||||||||
| | | | |
2017
|
| |||||||
Computers
|
| | | $ | 282 | | | | | $ | 128 | | |
Office furniture and equipment
|
| | | | 118 | | | | | | 96 | | |
Molds
|
| | | | 914 | | | | | | 737 | | |
Leasehold improvements
|
| | | | 149 | | | | | | 120 | | |
| | | | | 1,463 | | | | | | 1,081 | | |
Less: accumulated depreciation
|
| | | | (919) | | | | | | (735) | | |
Total property and equipment, net
|
| | | $ | 544 | | | | | $ | 346 | | |
| | | | ||||||||||
| | | | |
2017
|
| |||||||
Employees and related expenses
|
| | | $ | 5,473 | | | | | $ | 4,014 | | |
Government institutions
|
| | | | 1,232 | | | | | | 1,070 | | |
Income tax
|
| | | | 324 | | | | | | 1,024 | | |
Other
|
| | | | 2,136 | | | | | | 1,149 | | |
Total other liabilities
|
| | | $ | 9,165 | | | | | $ | 7,257 | | |
| Year ending December 31: | | | | | | | |
|
2019
|
| | | $ | 392 | | |
|
2020
|
| | | | 399 | | |
|
2021
|
| | | | 405 | | |
|
2022
|
| | | | 119 | | |
|
Total future minimum lease payments
|
| | | $ | 1,315 | | |
| | |
Year ended December 31,
|
| |||||||||||||||||||||
| | | | |
2017
|
| |||||||||||||||||||
| | |
Number
of Options |
| |
Weighted
average exercise price* |
| |
Number
of options |
| |
Weighted
Average Exercise price* |
| ||||||||||||
Outstanding at beginning of year
|
| | | | 6,728,398 | | | | | $ | 0.53 | | | | | | 2,559,080 | | | | | $ | 0.47 | | |
Changes during the year: | | | | | | | | | | | | | | | | | | | | | | | | | |
Granted
|
| | | | 212,176 | | | | | | 6.22 | | | | | | 5,596,535 | | | | | | 0.56 | | |
Exercised
|
| | | | (287,204) | | | | | | 0.56 | | | | | | (79,517) | | | | | | 0.56 | | |
Forfeited
|
| | | | (44.720) | | | | | | 2.86 | | | | | | (1,070,390) | | | | | | 0.56 | | |
Expired
|
| | | | (43,060) | | | | | | 0.56 | | | | | | (277,310) | | | | | | 0.56 | | |
Outstanding at end of year
|
| | | | 6,565,592 | | | | | $ | 0.69 | | | | | | 6,728,398 | | | | | $ | 0.53 | | |
Exercisable at end of year
|
| | | | 6,359,323 | | | | | $ | 0.56 | | | | | | 4,897,677 | | | | | $ | 0.51 | | |
| | |
2018
|
| |
2017
|
|
Fair value of one ordinary share
|
| |
$4.86 – $6.32
|
| |
$0.48 – $3.12
|
|
Dividend yield
|
| |
0%
|
| |
0%
|
|
Expected volatility
|
| |
51.2%
|
| |
39% –50%
|
|
Risk-free interest rate
|
| |
2.96%
|
| |
0.82% – 2.26%
|
|
Early exercise multiple (“EEM”)
|
| |
150% – 250%
|
| |
150% – 250%
|
|
Contractual term
|
| |
7 years
|
| |
7 years
|
|
| | |
Year ended December 31,
|
| |||||||||||||||||||||
| | | | |
2017
|
| |||||||||||||||||||
| | |
Number
of options |
| |
Weighted
average exercise price* |
| |
Number
of options |
| |
Weighted
average exercise price* |
| ||||||||||||
Outstanding at beginning of year
|
| | | | 2,725,544 | | | | | $ | 0.54 | | | | | | 1,725,491 | | | | | $ | 0.52 | | |
Changes during the year – | | | | | | | | | | | | | | | | | | | | | | | | | |
Granted
|
| | | | 145,804 | | | | | | 6.32 | | | | | | 1,212,050 | | | | | | 0.56 | | |
Exercised
|
| | | | (44,725) | | | | | | 0.56 | | | | | | (20,574) | | | | | | 0.56 | | |
Forfeited
|
| | | | — | | | | | | — | | | | | | (178,900) | | | | | | 0.56 | | |
Expired
|
| | | | — | | | | | | — | | | | | | (12,523) | | | | | | 0.56 | | |
Outstanding at end of year
|
| | | | 2,826,623 | | | | | $ | 0.84 | | | | | | 2,725,544 | | | | | $ | 0.54 | | |
Exercisable at end of year
|
| | | | 2,715,021 | | | | | $ | 0.61 | | | | | | 1,862,796 | | | | | $ | 0.53 | | |
| | |
2018
|
| |
2017
|
|
Fair value of one ordinary share
|
| |
$6.32
|
| |
$0.45 – $4.11
|
|
Dividend yield
|
| |
0%
|
| |
0%
|
|
Expected volatility
|
| |
51.2%
|
| |
39% –50%
|
|
Risk-free interest rate
|
| |
2.96%
|
| |
0.82% – 2.26%
|
|
Early exercise multiple
|
| |
150% – 250%
|
| |
150% – 250%
|
|
Contractual term
|
| |
7 years
|
| |
7 years
|
|
| | |||||||||||||||||||||||||
|
Options outstanding
|
| |
Options exercisable
|
| |||||||||||||||||||||
|
Exercise
prices* |
| |
Number of
options outstanding at end of year |
| |
Weighted
average remaining contractual life |
| |
Number of
options exercisable at end of year |
| |
Weighted
average remaining contractual life |
| ||||||||||||
|
$0.20
|
| | | | 724,546 | | | | | | 1.86 | | | | | | 724,546 | | | | | | 1.86 | | |
|
$0.44
|
| | | | 198,579 | | | | | | 3.87 | | | | | | 198,579 | | | | | | 3.87 | | |
|
$0.56
|
| | | | 8,132,578 | | | | | | 4.51 | | | | | | 8,072,773 | | | | | | 4.51 | | |
|
$6.32
|
| | | | 336,512 | | | | | | 6.72 | | | | | | 73,228 | | | | | | 6.72 | | |
| | |
Year ended December 31,
|
| |||||||||
| | | | |
2017
|
| |||||||
Cost of sales
|
| | | $ | 25 | | | | | $ | 36 | | |
Research and development expenses
|
| | | | 63 | | | | | | 21 | | |
Selling and marketing expenses
|
| | | | 1,817 | | | | | | 2,277 | | |
General and administrative expenses
|
| | | | 42 | | | | | | 102 | | |
| | | | $ | 1,947 | | | | | $ | 2,436 | | |
| | |
2018
|
| |
2017
|
| ||||||
Balance as of January 1
|
| | | $ | 3,066 | | | | | $ | 183 | | |
Adjustment to redemption value of redeemable non-controlling interest
|
| | | | 535 | | | | | | 1,154 | | |
Increases due to additional investment of redeemable non-controlling interest
|
| | | | — | | | | | | 1,729 | | |
Waiver of redeemable non-controlling interest
|
| | | | (1,414) | | | | | | — | | |
Balance as of December 31
|
| | | $ | 2,187 | | | | | $ | 3,066 | | |
| | | | ||||||||||
| | | | |
2017
|
| |||||||
Deferred tax assets in respect of: | | | | | | | | | | | | | |
Subsidiary net operating loss
|
| | | $ | 291 | | | | | $ | 253 | | |
Other temporary differences
|
| | | | 353 | | | | | | 256 | | |
Share-based compensation
|
| | | | 956 | | | | | | 554 | | |
Total deferred tax asset before valuation allowance
|
| | | | 1,600 | | | | | | 1,063 | | |
Valuation allowance
|
| | | | (291) | | | | | | (253) | | |
Total deferred tax asset
|
| | | | 1,309 | | | | | | 810 | | |
Deferred tax lability in respect to other comprehensive income
|
| | | | (11) | | | | | | (106) | | |
Total deferred tax liability
|
| | | | (11) | | | | | | (106) | | |
Deferred tax asset, net
|
| | | $ | 1,298 | | | | | $ | 704 | | |
| | |
Year ended December 31,
|
| |||||||||
| | | | |
2017
|
| |||||||
Income before taxes on income
|
| | | $ | 23,625 | | | | | $ | 9,799 | | |
Theoretical tax expenses at the statutory rate
|
| | | | 23% | | | | | | 24% | | |
| | | | | 5,434 | | | | | | 2,352 | | |
Increase (decrease) in taxes on income due to:
|
| | | | | | | | | | | | |
Benefits to the Benefited Enterprise
|
| | | $ | (5,162) | | | | | $ | (2,256) | | |
Different effective tax rates applicable to the subsidiaries
|
| | | | 53 | | | | | | 87 | | |
Changes in tax rate in the United States
|
| | | | — | | | | | | 406 | | |
Valuation allowance
|
| | | | 91 | | | | | | 119 | | |
Uncertain tax position
|
| | | | 771 | | | | | | — | | |
Non-deductible expenses
|
| | | | 73 | | | | | | 247 | | |
Previous year
|
| | | | — | | | | | | 25 | | |
| | | | $ | 1,260 | | | | | $ | 980 | | |
Jurisdiction
|
| |
Years
|
|
Israel | | |
2014 – 2018
|
|
The United States | | |
2015 – 2018
|
|
Japan | | |
2014 – 2018
|
|
United Kingdom | | |
2014 – 2018
|
|
Canada | | |
2014 – 2018
|
|
China | | |
2016 – 2018
|
|
Spain | | |
2018
|
|
| | |
Year ended December 31,
|
| |||||||||
| | | | |
2017
|
| |||||||
| | | $ | 22,049 | | | | | $ | 9,400 | | | |
Subsidiaries outside Israel
|
| | | | 1,576 | | | | | | 399 | | |
| | | | $ | 23,625 | | | | | $ | 9,799 | | |
| | |
Year ended December 31,
|
| |||||||||
| | | | |
2017
|
| |||||||
Current: | | | | | | | | | | | | | |
In Israel
|
| | | $ | 3 | | | | | $ | — | | |
| | | | 1,850 | | | | | | 1,535 | | | |
| | | | $ | 1,853 | | | | | $ | 1,535 | | |
Previous year: | | | | | | | | | | | | | |
In Israel
|
| | | | — | | | | | | 25 | | |
| | | | | — | | | | | | 25 | | |
Deferred: | | | | | | | | | | | | | |
In Israel
|
| | | | (94) | | | | | | — | | |
| | | | (499) | | | | | | (580) | | | |
| | | | | (593) | | | | | | (580) | | |
Total taxes on incomes
|
| | | $ | 1,260 | | | | | $ | 980 | | |
| | |
Year ended December 31, 2018
|
| |||
Balance at January 1, 2018
|
| | | $ | — | | |
Increase in uncertain tax positions for the current year
|
| | | | 771 | | |
Balance at December 31, 2018
|
| | | $ | 771 | | |
| | |
Year ended December 31,
|
| |||||||||
| | | | |
2017
|
| |||||||
North America
|
| | | $ | 89,350 | | | | | $ | 44,592 | | |
Europe
|
| | | | 5,692 | | | | | | 4,598 | | |
Asia-Pacific
|
| | | | 2,785 | | | | | | 3,136 | | |
Other
|
| | | | 2,335 | | | | | | 1,130 | | |
Total sales:
|
| | | $ | 100,162 | | | | | $ | 53,456 | | |
| | | | ||||||||||
| | | | |
2017
|
| |||||||
Balance as of January 1
|
| | | $ | 4,496 | | | | | $ | 406 | | |
Increases due to issuance of new contracts, excluding amounts recognized as revenue during the period
|
| | | | 6,302 | | | | | | 4,418 | | |
Revenue recognized that was included in the contract liability balance at the beginning of the period
|
| | | | (1,061) | | | | | | (328) | | |
Balance as of December 31
|
| | | $ | 9,737 | | | | | $ | 4,496 | | |
Contract liability presented in non-current liabilities(1)
|
| | | $ | 3,982 | | | | | $ | 3,362 | | |
Contract liability presented in current liabilities
|
| | | $ | 5,755 | | | | | $ | 1,134 | | |
| | | | | | ||||||||
Assets | | | | ||||||||||
CURRENT ASSETS: | | | | ||||||||||
Cash and cash equivalents
|
| | | $ | 18,951 | | | | | $ | 24,721 | | |
Marketable securities
|
| | | | 29,045 | | | | | | 26,532 | | |
Short-term bank deposits
|
| | | | 16,087 | | | | | | 10,045 | | |
Accounts receivable, net of allowance for doubtful accounts
|
| | | | 6,746 | | | | | | 7,008 | | |
Other receivables
|
| | | | 1,625 | | | | | | 2,495 | | |
Inventories
|
| | | | 7,092 | | | | | | 6,963 | | |
TOTAL CURRENT ASSETS
|
| | | $ | 79,546 | | | | | $ | 77,764 | | |
NON-CURRENT ASSETS: | | | | ||||||||||
Accounts receivable
|
| | | $ | 600 | | | | | $ | 544 | | |
Deferred offering costs
|
| | | | 990 | | | | | | 895 | | |
Deferred income taxes, net
|
| | | | 1,375 | | | | | | 1,309 | | |
Property and equipment, net
|
| | | | 859 | | | | | | 544 | | |
Operating lease right-of-use assets
|
| | | | 1,697 | | | | | | — | | |
TOTAL NON-CURRENT ASSETS
|
| | | | 5,521 | | | | | | 3,292 | | |
TOTAL ASSETS
|
| | | $ | 85,067 | | | | | $ | 81,056 | | |
Liabilities and Shareholders’ Equity | | | | ||||||||||
CURRENT LIABILITIES: | | | | ||||||||||
Accounts payable
|
| | | $ | 3,589 | | | | | $ | 4,509 | | |
Contract liabilities
|
| | | | 8,557 | | | | | | 5,755 | | |
Other liabilities
|
| | | | 9,343 | | | | | | 9,165 | | |
Accrued contingencies
|
| | | | — | | | | | | 10,000 | | |
TOTAL CURRENT LIABILITIES
|
| | | $ | 21,489 | | | | | $ | 29,429 | | |
NON-CURRENT LIABILITIES: | | | | ||||||||||
Contract liabilities
|
| | | $ | 4,091 | | | | | $ | 3,982 | | |
Other liabilities
|
| | | | 771 | | | | | | 771 | | |
Operating lease liabilities
|
| | | | 1,109 | | | | | | — | | |
Deferred income taxes, net
|
| | | | 31 | | | | | | 11 | | |
TOTAL NON-CURRENT LIABILITIES
|
| | | | 6,002 | | | | | | 4,764 | | |
TOTAL LIABILITIES
|
| | | $ | 27,491 | | | | | $ | 34,193 | | |
COMMITMENTS AND CONTINGENCIES (Note 4)
|
| | | ||||||||||
REDEEMABLE NON-CONTROLLING INTEREST
|
| | | $ | 2,252 | | | | | $ | 2,187 | | |
SHAREHOLDERS’ EQUITY: | | | | ||||||||||
Ordinary shares, NIS 0.01 par value, – authorized: 100,000,000 at March 31, 2019 and December 31, 2018; issued and outstanding: 26,946,737 and 26,682,413 shares at March 31, 2019 and December 31, 2018, respectively
|
| | | $ | 75 | | | | | $ | 74 | | |
Additional paid-in capital
|
| | | | 10,675 | | | | | | 10,152 | | |
Retained earnings
|
| | | | 43,030 | | | | | | 32,971 | | |
Accumulated other comprehensive income
|
| | | | 103 | | | | | | 66 | | |
InMode Ltd. shareholders’ equity
|
| | | | 53,883 | | | | | | 43,263 | | |
Non-controlling interests
|
| | | | 1,441 | | | | | | 1,413 | | |
TOTAL SHAREHOLDERS’ EQUITY
|
| | | | 55,324 | | | | | | 44,676 | | |
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
|
| | | $ | 85,067 | | | | | $ | 81,056 | | |
|
| | |
Three months ended March 31,
|
| |||||||||
| | | | |
2018
|
| |||||||
REVENUES
|
| | | $ | 30,552 | | | | | $ | 20,911 | | |
COST OF REVENUES
|
| | | | 4,271 | | | | | | 3,532 | | |
GROSS PROFIT
|
| | | | 26,281 | | | | | | 17,379 | | |
OPERATING EXPENSES: | | | | ||||||||||
Research and development
|
| | | | 1,199 | | | | | | 880 | | |
Sales and marketing
|
| | | | 14,097 | | | | | | 9,665 | | |
General and administrative
|
| | | | 1,053 | | | | | | 895 | | |
TOTAL OPERATING EXPENSES
|
| | | | 16,349 | | | | | | 11,440 | | |
INCOME FROM OPERATIONS
|
| | | | 9,932 | | | | | | 5,939 | | |
Finance income, net
|
| | | | 403 | | | | | | 278 | | |
INCOME BEFORE TAXES
|
| | | | 10,335 | | | | | | 6,217 | | |
INCOME TAX (TAX BENEFIT)
|
| | | | 177 | | | | | | (149) | | |
NET INCOME
|
| | | | 10,158 | | | | | | 6,366 | | |
Less: Net income attributable to non-controlling interests
|
| | | | (34) | | | | | | — | | |
NET INCOME ATTRIBUTABLE TO CONTROLLING INTEREST
|
| | | $ | 10,124 | | | | | $ | 6,366 | | |
NET INCOME PER SHARE : | | | | ||||||||||
Basic
|
| | | $ | 0.38 | | | | | $ | 0.22 | | |
Diluted
|
| | | $ | 0.28 | | | | | $ | 0.17 | | |
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED
IN COMPUTATION OF NET INCOME PER SHARE |
| | | ||||||||||
Basic
|
| | | | 26,818,179 | | | | | | 26,497,050 | | |
Diluted
|
| | | | 35,457,601 | | | | | | 34,711,741 | | |
| | |
Three months ended March 31,
|
| |||||||||
| | | | |
2018
|
| |||||||
NET INCOME
|
| | | $ | 10,158 | | | | | $ | 6,366 | | |
OTHER COMPREHENSIVE INCOME: | | | | ||||||||||
Change in foreign currency translation adjustment
|
| | | | (34) | | | | | | (2) | | |
Change in net unrealized gains of marketable securities, net of tax
|
| | | | 65 | | | | | | (45) | | |
TOTAL COMPREHENSIVE INCOME, net
|
| | | | 10,189 | | | | | | 6,319 | | |
Less: Comprehensive income attributable to non-controlling interests
|
| | | | (28) | | | | | | — | | |
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO CONTROLLING INTEREST
|
| | | $ | 10,161 | | | | | $ | 6,319 | | |
| | |
InMode Ltd. Shareholders’ Equity
|
| |
Non-controlling
Interests |
| |
Total
|
| |||||||||||||||||||||||||||||||||
| | |
Ordinary Shares
|
| |
Additional
paid-in capital |
| |
Retained
earnings |
| |
Accumulated
other comprehensive income |
| ||||||||||||||||||||||||||||||
| | |
Number of
shares issued |
| |
Amount
|
| ||||||||||||||||||||||||||||||||||||
BALANCE AS OF JANUARY 1,
2018, as previously reported |
| | | | 26,350,484 | | | | | | 74 | | | | | $ | 8,019 | | | | | $ | 10,819 | | | | | $ | 541 | | | | | | — | | | | | $ | 19,453 | | |
Impact of adoption of ASU 2016-01
|
| | | | — | | | | | | — | | | | | | — | | | | | | 316 | | | | | | (316) | | | | | | — | | | | | | — | | |
BALANCE AS OF JANUARY 1,
2018, as adjusted |
| | | | 26,350,484 | | | | | | 74 | | | | | | 8,019 | | | | | | 11,135 | | | | | | 225 | | | | | | — | | | | | | 19,453 | | |
CHANGES DURING THE THREE MONTHS ENDED MARCH 31, 2018:
|
| | | | | | | | |||||||||||||||||||||||||||||||||||
Net income
|
| | | | — | | | | | | — | | | | | | — | | | | | | 6,366 | | | | | | — | | | | | | — | | | | | | 6,366 | | |
Other comprehensive income, net
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (47) | | | | | | — | | | | | | (47) | | |
Share-based compensation
|
| | | | — | | | | | | — | | | | | | 833 | | | | | | — | | | | | | — | | | | | | — | | | | | | 833 | | |
Adjustment to redemption value of redeemable non-controlling interest
|
| | | | — | | | | | | — | | | | | | — | | | | | | (431) | | | | | | — | | | | | | — | | | | | | (431) | | |
Exercise of options
|
| | | | 267,189 | | | | | | * | | | | | | 150 | | | | | | — | | | | | | — | | | | | | — | | | | | | 150 | | |
BALANCE AT MARCH 31, 2018
|
| | | | 26,617,673 | | | | | | 74 | | | | | $ | 9,002 | | | | | $ | 17,070 | | | | | $ | 178 | | | | | | — | | | | | $ | 26,324 | | |
BALANCE AS OF JANUARY 1,
2019 |
| | | | 26,682,413 | | | | | | 74 | | | | | $ | 10,152 | | | | | $ | 32,971 | | | | | $ | 66 | | | | | | 1,413 | | | | | $ | 44,676 | | |
CHANGES DURING THE THREE MONTHS ENDED MARCH 31, 2019:
|
| | | | | | | | |||||||||||||||||||||||||||||||||||
Net income
|
| | | | — | | | | | | — | | | | | | — | | | | | | 10,124 | | | | | | — | | | | | | 34 | | | | | | 10,158 | | |
Other comprehensive income, net
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 37 | | | | | | (6) | | | | | | 31 | | |
Share-based compensation
|
| | | | — | | | | | | — | | | | | | 402 | | | | | | — | | | | | | — | | | | | | — | | | | | | 402 | | |
Adjustment to redemption value of redeemable non-controlling interest
|
| | | | — | | | | | | — | | | | | | — | | | | | | (65) | | | | | | — | | | | | | — | | | | | | (65) | | |
Exercise of options
|
| | | | 264,324 | | | | | | 1 | | | | | | 121 | | | | | | — | | | | | | — | | | | | | — | | | | | | 122 | | |
BALANCE AT MARCH 31, 2019
|
| | | | 26,946,737 | | | | | | 75 | | | | | $ | 10,675 | | | | | $ | 43,030 | | | | | $ | 103 | | | | | | 1,441 | | | | | $ | 55,324 | | |
| | |
Three months ended March 31,
|
| |||||||||
| | | | |
2018
|
| |||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | | | | ||||||||||
Net income
|
| | | $ | 10,158 | | | | | $ | 6,366 | | |
Adjustments required to reconcile net income to net cash provided by operating activities:
|
| | | ||||||||||
Depreciation and amortization
|
| | | | 63 | | | | | | 35 | | |
Share-based compensation
|
| | | | 402 | | | | | | 833 | | |
Allowance for doubtful accounts expenses
|
| | | | 59 | | | | | | (73) | | |
Gains on marketable securities, net
|
| | | | — | | | | | | (33) | | |
Changes in fair value of marketable securities, net
|
| | | | — | | | | | | (6) | | |
Finance income, net
|
| | | | (183) | | | | | | — | | |
Provision for deferred income taxes, net
|
| | | | (66) | | | | | | (4) | | |
Changes in operating assets and liabilities:
|
| | | ||||||||||
Decrease (increase) in accounts receivable
|
| | | | 147 | | | | | | (564) | | |
Decrease in other receivables
|
| | | | 873 | | | | | | 251 | | |
Increase in inventories
|
| | | | (129) | | | | | | (824) | | |
Increase (decrease) in accounts payable
|
| | | | (1,015) | | | | | | 487 | | |
Increase (decrease) in other liabilities
|
| | | | (449) | | | | | | 183 | | |
Increase in contract liabilities
|
| | | | 2,911 | | | | | | 746 | | |
Decrease in accrued contingencies
|
| | | | (10,000) | | | | | | — | | |
Net cash provided by operating activities
|
| | | $ | 2,771 | | | | | $ | 7,397 | | |
CASH FLOWS FROM INVESTING ACTIVITIES: | | | | ||||||||||
Investment in short-term deposit
|
| | | | (11,000) | | | | | | — | | |
Proceeds from short-term deposit
|
| | | | 5,000 | | | | | | — | | |
Purchase of fixed assets
|
| | | | (378) | | | | | | (45) | | |
Purchase of marketable securities
|
| | | | (4,918) | | | | | | (2,444) | | |
Proceeds from sale of marketable securities
|
| | | | 2,603 | | | | | | 496 | | |
Net cash used in investing activities
|
| | | $ | (8,693) | | | | | $ | (1,993) | | |
CASH FLOWS FROM FINANCING ACTIVITIES: | | | | ||||||||||
Exercise of options
|
| | | $ | 122 | | | | | $ | 150 | | |
Net cash provided by financing activities
|
| | | | 122 | | | | | | 150 | | |
EFFECT OF EXCHANGE RATE CHANGES ON CASH
|
| | | | 30 | | | | | | (11) | | |
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
|
| | | | (5,770) | | | | | | 5,543 | | |
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD
|
| | | | 24,721 | | | | | | 17,593 | | |
CASH AND CASH EQUIVALENTS AT END OF PERIOD
|
| | | $ | 18,951 | | | | | $ | 23,136 | | |
SUPPLEMENTAL DISCLOSURES OF CASH FLOWS INFORMATION: | | | | ||||||||||
Income taxes paid
|
| | | $ | — | | | | | $ | 42 | | |
Interest received
|
| | | $ | 213 | | | | | $ | 136 | | |
NON CASH FINANCING ACTIVITIES | | | | ||||||||||
Deferred offering costs in accounts payable
|
| | | $ | 95 | | | | | $ | — | | |
Operating lease right-of-use assets
|
| | | $ | 245 | | | | | $ | — | | |
| | | | | | ||||||||
Government securities*
|
| | | $ | 24,022 | | | | | $ | 21,932 | | |
Corporate debt securities
|
| | | | 5,023 | | | | | | 4,600 | | |
Total
|
| | | $ | 29,045 | | | | | $ | 26,532 | | |
| | | | ||||||||||||||||||||||
| | |
Fair
value |
| |
Cost or
amortized cost |
| |
Gross
unrealized holding gains |
| |
Gross
unrealized holding loss |
| ||||||||||||
Level 2 securities: | | | | | | | | | | | | | | | | | | | | | | | | | |
Government securities
|
| | | $ | 24,022 | | | | | $ | 23,913 | | | | | $ | — | | | | | $ | 109 | | |
Corporate debt securities
|
| | | | 5,023 | | | | | | 4,998 | | | | | | (6) | | | | | | 31 | | |
Total
|
| | | $ | 29,045 | | | | | $ | 28,911 | | | | | $ | (6) | | | | | $ | 140 | | |
|
| | | | ||||||||||||||||||||||
| | |
Fair
value |
| |
Cost or
amortized cost |
| |
Gross
unrealized holding gains |
| |
Gross
unrealized holding loss |
| ||||||||||||
Level 2 securities: | | | | | | | | | | | | | | | | | | | | | | | | | |
Government securities
|
| | | $ | 21,932 | | | | | $ | 21,878 | | | | | $ | (3) | | | | | $ | 57 | | |
Corporate debt securities
|
| | | | 4,600 | | | | | | 4,606 | | | | | | (15) | | | | | | 9 | | |
Total
|
| | | $ | 26,532 | | | | | $ | 26,484 | | | | | $ | (18) | | | | | $ | 66 | | |
| | |
Market value
|
| |||||||||
| | | | | | ||||||||
Due within one year
|
| | | $ | 14,826 | | | | | $ | 12,801 | | |
1 to 2 years
|
| | | | 10,094 | | | | | | 9,068 | | |
2 to 3 years
|
| | | | 2,022 | | | | | | 2,609 | | |
3 to 4 years
|
| | | | 2,103 | | | | | | 2,054 | | |
Total
|
| | | $ | 29,045 | | | | | $ | 26,532 | | |
| | | | | | ||||||||
Raw materials
|
| | | $ | 2,501 | | | | | $ | 2,508 | | |
Finished products
|
| | | | 4,591 | | | | | | 4,455 | | |
Total inventories
|
| | | $ | 7,092 | | | | | $ | 6,963 | | |
| | |
Three months ended
March 31, 2019 |
| |||||||||
| | |
Number
of options |
| |
Weighted
average exercise price* |
| ||||||
Outstanding at beginning of period
|
| | | | 6,565,592 | | | | | $ | 0.69 | | |
Changes during the period: | | | | | | | | | | | | | |
Granted
|
| | | | 386,425 | | | | | | 7.49 | | |
Exercised
|
| | | | (40,699) | | | | | | 0.37 | | |
Expired
|
| | | | (4,473) | | | | | | 0.56 | | |
Outstanding at end of period
|
| | | | 6,906,845 | | | | | $ | 1.08 | | |
Exercisable at end of period
|
| | | | 6,489,087 | | | | | $ | 0.68 | | |
| | |
2019
|
|
Fair value of one ordinary share
|
| |
$7.49
|
|
Dividend yield
|
| |
0%
|
|
Expected volatility
|
| |
51.91%
|
|
Risk-free interest rate
|
| |
2.56% – 2.60%
|
|
Early exercise multiple (EEM)
|
| |
150% – 250%
|
|
Contractual term
|
| |
7 years
|
|
| | |
Three months ended
March 31, 2019 |
| |||||||||
| | |
Number
of options |
| |
Weighted
average exercise price* |
| ||||||
Outstanding at beginning of period
|
| | | | 2,826,623 | | | | | $ | 0.84 | | |
Changes during the period: | | | | | | | | | | | | | |
Granted
|
| | | | 89,450 | | | | | | 7.49 | | |
Exercised
|
| | | | (223,625) | | | | | | 0.48 | | |
Outstanding at end of period
|
| | | | 2,692,448 | | | | | $ | 1.09 | | |
Exercisable at end of period
|
| | | | 2,547,975 | | | | | $ | 0.76 | | |
| | |
2019
|
|
Fair value of one ordinary share
|
| |
$7.49
|
|
Dividend yield
|
| |
0%
|
|
Expected volatility
|
| |
51.91%
|
|
Risk-free interest rate
|
| |
2.60%
|
|
Early exercise multiple
|
| |
150% – 250%
|
|
Contractual term
|
| |
7 years
|
|
| | |||||||||||||||||||||||||
|
Options outstanding
|
| |
Options exercisable
|
| |||||||||||||||||||||
|
Exercise
prices* |
| |
Number of
options outstanding at end of period |
| |
Weighted
average remaining contractual life |
| |
Number of
options exercisable at end of period |
| |
Weighted
average remaining contractual life |
| ||||||||||||
|
$0.20
|
| | | | 703,078 | | | | | | 1.66 | | | | | | 703,078 | | | | | | 1.66 | | |
|
$0.44
|
| | | | 55,459 | | | | | | 3.28 | | | | | | 55,459 | | | | | | 3.28 | | |
|
$0.56
|
| | | | 8,028,369 | | | | | | 4.37 | | | | | | 8,028,369 | | | | | | 4.37 | | |
|
$6.32
|
| | | | 336,512 | | | | | | 6.47 | | | | | | 140,616 | | | | | | 6.47 | | |
|
$7.49
|
| | | | 475,875 | | | | | | 6.77 | | | | | | 109,540 | | | | | | 6.77 | | |
| | |
Three months ended
March 31, |
| |||||||||
| | | | |
2018
|
| |||||||
Cost of revenues
|
| | | $ | 19 | | | | | $ | 11 | | |
Research and development expenses
|
| | | | 52 | | | | | | 6 | | |
Sales and marketing expenses
|
| | | | 308 | | | | | | 803 | | |
General and administrative expenses
|
| | | | 23 | | | | | | 13 | | |
Total
|
| | | $ | 402 | | | | | $ | 833 | | |
| | | | ||||
Operating lease cost
|
| | | $ | 177 | | |
| | | | ||||
Operating cash flows from operating leases
|
| | | $ | 181 | | |
| | | | ||||
Operating Leases | | | | | | | |
Operating lease right-of-use assets
|
| | | $ | 1,697 | | |
Other current liabilities
|
| | | | 627 | | |
Operating lease liabilities
|
| | | | 1,109 | | |
Total operating lease liabilities
|
| | | $ | 1,736 | | |
Weighted Average Remaining Lease Term | | | | | | | |
Operating leases
|
| |
2.77 years
|
| |||
Weighted Average Discount Rate | | | | | | | |
Operating leases
|
| | | | 2.75% | | |
| | |
Operating
Leases |
| |||
Year Ending March 31, | | | | | | | |
| | | $ | 508 | | | |
2021
|
| | | | 603 | | |
2022
|
| | | | 618 | | |
Thereafter
|
| | | | 71 | | |
Total lease payments
|
| | | | 1,800 | | |
Less imputed interests
|
| | | | (64) | | |
Total
|
| | | $ | 1,736 | | |
| Year Ending December 31: | | | | | | | |
|
2019
|
| | | $ | 392 | | |
|
2020
|
| | | | 399 | | |
|
2021
|
| | | | 405 | | |
|
2022
|
| | | | 119 | | |
|
Total future minimum lease payments
|
| | | $ | 1,315 | | |
| | | | ||||
Balance at December 31, 2018
|
| | | $ | 9,737 | | |
Increases due to issuance of new contracts, excluding amounts recognized as revenue during the period
|
| | | | 6,195 | | |
Revenue recognized that was included in the contract liability balance at the beginning of the period
|
| | | | (3,284) | | |
Balance at March 31, 2019
|
| | | $ | 12,648 | | |
Contract liability presented in non-current liabilities(1)
|
| | | | 4,091 | | |
Contract liability presented in current liabilities
|
| | | $ | 8,557 | | |
This ‘424B4’ Filing | Date | Other Filings | ||
---|---|---|---|---|
3/31/20 | ||||
2/28/20 | ||||
12/31/19 | ||||
9/1/19 | ||||
8/31/19 | ||||
8/12/19 | ||||
Filed on: | 8/8/19 | EFFECT | ||
8/7/19 | CERT, EFFECT | |||
7/26/19 | ||||
7/24/19 | ||||
7/1/19 | DRS/A | |||
6/30/19 | ||||
6/27/19 | ||||
6/15/19 | ||||
5/5/19 | ||||
4/30/19 | ||||
4/6/19 | ||||
4/5/19 | ||||
4/1/19 | ||||
3/31/19 | ||||
3/13/19 | DRS/A | |||
2/28/19 | ||||
2/21/19 | ||||
1/13/19 | ||||
1/7/19 | ||||
1/6/19 | ||||
1/1/19 | ||||
12/31/18 | ||||
12/15/18 | ||||
9/17/18 | ||||
9/12/18 | ||||
8/30/18 | ||||
8/25/18 | ||||
7/31/18 | ||||
7/30/18 | ||||
7/24/18 | ||||
6/30/18 | ||||
6/17/18 | ||||
3/31/18 | ||||
2/15/18 | ||||
1/1/18 | ||||
12/31/17 | ||||
12/22/17 | ||||
11/2/17 | ||||
11/1/17 | ||||
6/14/17 | ||||
6/1/17 | ||||
5/31/17 | ||||
4/5/17 | ||||
4/1/17 | ||||
3/31/17 | ||||
1/1/17 | ||||
12/31/16 | ||||
1/1/16 | ||||
3/4/14 | ||||
1/1/14 | ||||
4/5/12 | ||||
1/1/11 | ||||
3/16/08 | ||||
1/30/08 | ||||
1/2/08 | ||||
4/1/05 | ||||
List all Filings |